Clinical trials: Cirrhosis, Liver
Fibrosis
Transitional Care Interventions for Patients With Cirrhosis Post-TIPS
The investigators conducted a randomized controlled trial to describe if multidisciplinary and patient-centered transitional care interventions for patients with cirrhosis post-TIPS can improve compliance behavior and reduce…
- Trial name
- NCT02877953
- Testing
- the prevention of complications post-TIPS
- Volunteers
- 76 people
- Sponsor
- Shihezi University
Hepatic Encephalopathy
Post Transjugular Intrahepatic Portosystemic Shunt (Tips) Albumine Infusion to Prevent Hepatic Encephalopathy
The purpose of this study is to evaluate the efficacy of albumin infusion to prevent post tips hepatic encephalopathy'
- Trial name
- NCT01559519
- Testing
- Albumin
- Volunteers
- 20 people
- Sponsor
- University of Roma La Sapienza
Alzheimer Disease, Late Onset, Stroke
Explore the Sharing Model Intervene to Improve the Knowledge, Attitudes, Service Intentions and Service Start-up Effects of the Eight Major Non-cancer Disease End-stage Caregivers on Well-being and Palliative Care
Since September 1st, 2009, Taiwan has begun to pay attention to the care of patients with organ failure, dementia and the elderly, and brought eight of non-cancer terminal patients into health insurance subsidies to implement the…
- Conditions
- Alzheimer Disease, Late Onset, Stroke, Heart Failure, Pulmonary Disease, Chronic Obstructive
- Trial name
- NCT05407272
- Testing
- Health Education Manual, manual
- Where
- Taiwan
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Wen-Shiou Pan
Decompensated Cirrhosis
Management of Decompensated HCV Cirrhotic Patients
-The limited treatment varieties of decompensated cirrhosis due to hepatitis C virus (HCV) remain a challenge. In patients with reduced hepatic reserve, DAAs may be associated with complications as worsening decompensation.
- Trial name
- NCT03547895
- Testing
- Sofosbuvir 400mg (Sovaldi) + Daclatasvir 60 mg (Daklinza) + Ribavirin 200 mg (Rebetol), vitamin K (Phytomenadione) 10 mg+ furosemide and spironolactone (Lasilactone) 50 mg + milk thistle (Silymarin) 140 mg + Albumin infusion
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Zagazig University
Liver Cirrhosis, Gastrointestinal Bleeding
Utilizing of Physiological Parameters Predict the Prognosis of Cirrhotic Patients With Gastrointestinal Bleeding
Can physiological indicators such as quick Sequential Organ Failure Assessment , Shock Index, and its derived indicators such as Modified Shock Index , Age Shock Index and Respiratory Adjusted Shock Index accurately predict the…
- Trial name
- SI (NCT06680583)
- Testing
- physical indicators such as shock index relatives
- Where
- Taiwan
- Volunteers
- 150 people
- Sponsor
- St. Martin De Porress Hospital
Liver Cirrhosis
Human Fetal Liver Cell Transplantation in Chronic Liver Failure
The herein study consists in the transplantation of liver progenitor cells isolated from human fetal liver tissue with the aim of improving conventional liver therapy and broadening therapeutical options other than liver…
- Trial name
- hFLCTx (NCT01013194)
- Testing
- Human Fetal Liver Cell Transplantation
- Where
- Italy
- Volunteers
- 25 people
- Sponsor
- The Mediterranean Institute for Transplantation and Advanced Specialized Therapies
Cirrhosis
Recombinant Human Granulocyte Monocyte - Colony Stimulating Factor (GM CSF) for Prevention of Pneumonia in Patients With Cirrhosis
Informed consent obtained from the patient or the patient's legal surrogate. The window for randomization and initiation of study drug infusion is 2 days from day of Admission.
- Trial name
- NCT03123666
- Testing
- GMCSF
- Where
- India
- Volunteers
- 160 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Chronic Hepatitis C, Fibrosis
Combination Drug Therapy for Patients With Hepatitis C
Hepatitis C is a major cause of liver disease in the United States and leads to cirrhosis of the liver in approximately one-third of patients some of whom will ultimately suffer from liver failure or liver cancer.
- Conditions
- Chronic Hepatitis C, Fibrosis, Hemolytic Anemia
- Trial name
- NCT00001729
- Testing
- Ribavirin
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Decompensated Cirrhosis of Liver
GCSF Therapy in Decompensated Cirrhosis - A Double Blinded RCT
Cirrhosis of liver is a leading cause of morbidity and mortality worldwide. Complications like ascites, spontaneous bacterial peritonitis, variceal bleed, hepatic encephalopathy, hepatorenal syndrome (HRS) and hepatocellular…
- Trial name
- NCT03911037
- Testing
- G-CSF
- Where
- India
- Volunteers
- 70 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Primary Biliary Cholangitis
Study of [14C]CS0159 in China Healthy Subjects
Study of [14C]CS0159 in China Healthy Subjects.
- Trial name
- NCT06098027
- Testing
- [14C]CS0159
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Cascade Pharmaceuticals, Inc
Morbid Obesity, Non Alcoholic Steatohepatitis
Non Invasive Measurements of Fibrosis, Inflammation and Steatohepatitis in Morbidly Obese Patients
Abstract: Fatty liver most frequently corresponds to a fat overload of the liver. It is usually classified as alcoholic steatosis or non-alcoholic steatosis.
- Trial name
- FIRM (NCT01695083)
- Where
- France
- Volunteers
- 186 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Liver Cirrhosis
A Study to Compare How Different Medicines (Rosuvastatin, Digoxin, Metformin, and Furosemide) Are Handled by the Body of Healthy People and People With Liver Cirrhosis
This study is open to healthy adults and adults with liver cirrhosis. The purpose of this study is to compare how different medicines are handled by the body in people with and without liver cirrhosis.
- Trial name
- NCT05741372
- Testing
- Rosuvastatin, Digoxin, Metformin hydrochlorid
- Where
- Germany
- Volunteers
- 28 people
- Sponsor
- Boehringer Ingelheim
Portal Hypertension
Standard Therapy and TIPS for Moderate to High-risk Esophageal and Gastric Variceal Bleeding
Comparison of endoscopic therapy combined with non-selective therapy β Receptor blockers (NSBBs) and TIPS in the treatment of liver cirrhosis The impact of reducing bleeding on the survival of critically ill patients.
- Trial name
- NCT06013670
- Testing
- Endoscopy+NSBBs, Transjugular intrahepatic portosystemic shunt
- Where
- China
- Volunteers
- 86 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Cirrhosis, Liver, Gastroesophageal Varices
Development of 4D Flow MRI for Risk Stratification of Variceal Bleeding in Cirrhosis
The goal of this research is to validate novel non-invasive Magnetic resonance imaging (MRI) biomarkers to detect Gastroesophageal varices (GEV) in patients with cirrhosis, including fractional flow change in the portal vein and…
- Conditions
- Cirrhosis, Liver, Gastroesophageal Varices, Fontan Procedure
- Trial name
- NCT04867954
- Testing
- Ensure Plus®, Pre-clinical validation contrast enhanced MRI, Clinical validation MRI
- Where
- United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Intrahepatic Cholangiocarcinoma (Icc)
Liquid Biopsy Using Exosomal miRNA Enables Risk Stratification of Potential Metastasis in Patients With Intrahepatic Cholangiocarcinoma.
Occult metastasis at the time of surgery is a major driver of poor outcomes in intrahepatic cholangiocarcinoma (ICC), yet reliable preoperative biomarkers to identify such patients are lacking.
- Trial name
- EXOMIC (NCT07224737)
- Testing
- EXOMIC small RNA sequencing, EXOMIC assay (qRT-PCR validation)
- Where
- United States
- Volunteers
- 230 people
- Sponsor
- City of Hope Medical Center
Liver Cirrhosis, Periapical Lesions
Oral Health Status in Patients With Cirrhosis and Effect of Dental Treatment on MELD Score of Cirrhosis Patients
It has been found that there is an association between prevalence of odontogenic infection and systemic diseases.Cirrhosis has also been associated with poor oral health status.Treating those patients accordingly can help in…
- Trial name
- NCT04399512
- Testing
- Nonsurgical root canal treatment
- Where
- India
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Postgraduate Institute of Dental Sciences Rohtak
Acquired Bleeding Disorder, Cirrhosis
Safety and Efficacy of Activated Recombinant Human Factor VII in Cirrhotic Patients Undergoing Partial Hepatectomy
This trial is conducted in Asia. The aim of this trial is to evaluate the haemostatic efficacy of activated recombinant human factor VII in cirrhotic patients scheduled to undergo partial hepatectomy due to liver cancer or benign…
- Trial name
- NCT01562821
- Testing
- activated recombinant human factor VII
- Where
- 7 sites in China, Taiwan and 1 more
- Volunteers
- 235 people
- Sponsor
- Novo Nordisk A/S
Cirrhosis
Tadalafil for Erectile Dysfunction in Patients With Cirrhosis
This study will be conducted into two parts 1) Screening of 400 cases of cirrhosis (Child A,child B and child c) for the prevalence and risk factors of erectile dysfunction in cirrhosis.2) The part 2 is RCT as follows where 70…
- Trial name
- NCT03566914
- Testing
- Tadalafil 10 MG
- Where
- India
- Volunteers
- 140 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Cirrhosis, Liver, Splenectomy; Status
The Effect of Laparoscopic Splenectomy and Azygoportal Disconnection on Liver Reserve Function for Cirrhosis Patients
In this study, the investigators compared the improvement of liver reserve function related indicators in patients with liver cirrhosis after laparoscopic splenectomy and azygoportal disconnection.
- Conditions
- Cirrhosis, Liver, Splenectomy; Status, Portal Hypertension
- Trial name
- ELSDL (NCT05325437)
- Testing
- Laparoscopic splenectomy and azygoportal disconnection
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Northern Jiangsu People's Hospital
Microbiota, Hepatocellular Carcinoma
Probiotics in the Prevention of Hepatocellular Carcinoma in Cirrhosis
Background. The main risk factor for the development of hepatocellular carcinoma (HCC) is cirrhosis of any etiology, with an annual risk between 1 and 6%, being currently the leading cause of death in patients with cirrhosis and…
- Conditions
- Microbiota, Hepatocellular Carcinoma, Cirrhosis
- Trial name
- NCT03853928
- Testing
- Probiotics
- Volunteers
- 280 people
- Sponsor
- Austral University, Argentina
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.